COAGULATION
across different methodologies, often with short turnaround expectations. This diversity necessitates platforms that can deliver flexibility and precision without disrupting overall workflow.”
Stephen has worked in the Cambridge University Hospitals NHS Foundation Trust’s laboratory for almost 25 years, and is currently Consultant Clinical Scientist at the Addenbrooke’s Haemostasis Unit. As the regional referral centre for specialist haemostasis testing, Stephen’s laboratory serves as the primary investigative hub for thrombophilia and platelet function testing. It also provides critical support to the Haemophilia Comprehensive Care Centre and collaborates with affiliated hospitals across Cambridge, including Addenbrooke’s, the Rosie, and Royal Papworth.
Smaller machine, no compromises
Despite its compact footprint, sthemO 201 was found to accommodate a broad reagent range while maintaining consistently fast throughput. “Unlike many smaller platforms, it did
not require frequent manual interventions or system pauses when transitioning between complex tests, which allowed for seamless execution of complex testing where different combinations of tests are required on multiple samples at the same time,” Stephen noted.
Detection flexibility also featured
prominently in the assessment. The sthemO 201 incorporates four complementary detection technologies: mechanical (viscosity-based), optical, turbidimetric, and immuno- chemiluminescent. This integrated approach allows each assay to be paired with the most appropriate detection principle and to be able to be run in parallel on a single platform, without the need for multiple analysers and large footprints in often cramped laboratory spaces.
A key part of this configuration is
Stago’s unique viscosity-based detection system (VBDS), which identifies clot formation by monitoring mechanical resistance changes in a sample. This mechanical endpoint method provides a direct measure of clotting based on changes in sample viscosity, independent
Coagulation analysers are often considered to be among the more technically demanding instruments in a pathology laboratory, requiring familiarity with a wide range of test parameters, sample handling nuances, and result interpretation considerations.
of optical clarity. VBDS proved particularly useful in situations where samples were affected by lipaemia, haemolysis, or icterus – common in intensive care and surgical settings – offering stable endpoint detection in assays such as PT, APTT, and fibrinogen. Throughout the evaluation, VBDS contributed to consistent results across a range of sample types, supporting analytical confidence even under variable pre-analytical conditions. Importantly, the system’s mechanical detection does not operate in isolation,
but along with the platform’s optical, turbidimetric, and chemiluminescent capabilities. This combination enables laboratories to manage diverse assays on a single platform without needing to compromise on detection quality or operational efficiency.
The sthemO instruments also
introduce Stago’s new dual technology, combining simultaneous mechanical and optical measurements in a brand- new measuring cell. The ability to run clotting tests using VBDS and optical measurement at three different wavelengths at the same time will also open up opportunities for new clinical applications, according to Stago.
A reliable platform for high-complexity haemostasis testing without the need for multiple instruments or manual workarounds
18
Genuine walkaway technology Walkaway capability – “often promised, but inconsistently delivered”, according to Stephen – was a clear strength. In high complexity or high-volume testing environments, uninterrupted analyser
SEPTEMBER 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
